[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lipid-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lipid-disorder":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,52,85,125,154,181],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100630707","phase-1-a-safety-and-tolerability-trial-evaluating-ctx310-in-participants-with-refractory-dyslipidemias-100630707",false,"NCT07491172","A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias","A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias","Key Inclusion Criteria:\n\n1. Age of ≥18 and ≤75 years at the time of signing the informed consent.\n2. Able to provide written informed consent.\n3. Participants diagnosed with persistent dyslipidemias defined by TG ≥150 mg\u002FdL - and LDL-C ≥70 mg\u002FdL in participants with ASCVD, or LDL-C ≥70 or 100mg\u002FdL in participants with or without ASCVD respectively, or TG ≥500 mg\u002FdL.\n4. Refractory to the maximal intensity or MTD of standard of care lines of lipid-lowering therapies available through routine clinical care, for at least 12 weeks prior to screening\n5. Female participants must be postmenopausal or surgically sterile.\n6. All male participants and their female partners must agree to the use of an acceptable method of effective contraception for the duration of the study.\n\nExclusion Criteria:\n\n1. Participants with familial chylomicronemia syndrome (FCS). Some exceptions may apply.\n2. Evidence of liver disease, defined as but not limited to:\n\n   LFTS \\>2 × upper limit of normal (ULN), or total bilirubin \\>2 × ULN, or INR \\>1.5 × ULN, or liver stiffness measured by liver elastography\n3. Abnormal or compromised function of kidney, heart, blood or liver.\n4. Acute coronary syndrome event or stroke within 24 weeks prior to Day 1. Acute pancreatitis within 12 weeks prior to Day 1.\n5. Current use or use within 365 days from Day 1 of any hepatocyte-targeted small interfering RNA (except inclisiran).\n6. Positive serology for HIV, hepatitis B or hepatitis C (antibody, surface antigen orNAT). Serology consistent with prior immunization will be eligible for the trial.\n7. Any prior malignancy within the past 5 years, or current malignancy (exceptions for resected or removed basal cell carcinoma, squamous cell carcinoma in situ and carcinoma in situ of the cervix or breast).\n8. Women of childbearing potential.\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.\n\nNote: The inclusion and exclusion criteria listed represent the global protocol. Additional or modified eligibility criteria may apply in certain countries in accordance with local regulatory and ethics committee requirements and the approved country-specific protocol.","ALL","18 Years","75 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.",[27,28,29,30,31,32,33,34,35,36],"Cardiovascular","Metabolic Disease","Dyslipidemias","Lipid Disorder","Hypertriglyceridemia","Heterozygous Familial Hypercholesterolemia (HeFH)","Homozygous Familial Hypercholesterolemia (HoFH)","Severe Hypertriglyceridemia (sHTG)","Mixed Hyperlipemia","Hypercholesterolaemia",[38],"Refractory Dyslipidemias","RECRUITING","2026-05-19",{"date":42,"type":43},"2026-05-22","ACTUAL",{"date":45,"type":43},"2024-06-21",{"date":47,"type":21},"2028-06",{"name":49,"class":50},"CRISPR Therapeutics AG","INDUSTRY",18,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":18,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100553593","phase-2-emergency-medicine-cardiovascular-risk-assessment-for-lipid-disorders-trial-100553593","NCT06488105","Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial","Initiating Preventive Care for Hyperlipidemia in the Emergency Department: The EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders) Trial","EMERALD RCT","Inclusion Criteria\n\n1. Evaluation for Acute Coronary Syndrome\n2. Age 40-75 Years\n3. 10-year Atherosclerotic Cardiovascular Disease (ASCVD) Risk ≥7.5% or Known Diabetes or\n\nKnown ASCVD:\n\n1. Myocardial Infarction\n2. Unstable Angina\n3. Percutaneous Coronary Intervention\n4. Coronary Artery Bypass Graft\n5. Stroke\n6. Transient Ischemic Attack\n7. Peripheral Artery Disease\n\nExclusion Criteria\n\n1. ST-Segment Elevation Myocardial Infarction (STEMI) Activation\n2. ST Depression \\>1 mm in Contiguous Leads\n3. On a Lipid Lowering Agent (Statin, PCSK9 Inhibitor, Bempedoic Acid, Ezetimibe, Inclisiran, etc.)\n4. Inability to Return for 30-day Follow-up\n5. Unstable Vitals (Systolic blood pressure \\\u003C90, HR \\>120 or \\\u003C50, oxygen saturation \\\u003C90%)\n6. Statin Intolerance\n7. Any Resulted High-Sensitivity Troponin I ≥100 ng\u002FL\n8. End-stage renal disease (ESRD) and\u002For glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin\u002F1.73 m2\n9. Liver Cirrhosis\n10. Pregnancy\n11. Anticipated Hospitalization\n12. Life Expectancy \\\u003C1 Year\n13. Transfer from Another Hospital\n14. Prisoner\n15. Non-English Speaking","40 Years",{"count":62,"type":21},130,[64],"PHASE2","Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) is a protocolized intervention based on American College of Cardiology\u002FAmerican Heart Association and US Preventive Services Task Force guidelines designed to initiate preventive cardiovascular care for emergency department patients being evaluated for acute coronary syndrome. The overarching goals of this proposal are to (1) determine the efficacy of EMERALD at lowering low-density lipoprotein cholesterol (LDL-C) and non high-density lipoprotein cholesterol (non-HDL-C) among at-risk Emergency Department (ED) patients who are not already receiving guideline-directed outpatient preventive care and (2) inform our understanding of patient adherence and determinants of implementation for ED-based cardiovascular disease prevention strategies.",[30,67,68,69],"Hypercholesterolemia","Cardiovascular Diseases","Atherosclerosis",[71,72,73],"hyperlipidemia","cardiovascular disease","atherosclerotic cardiovascular disease","2026-02-26",{"date":76,"type":43},"2026-02-27",{"date":78,"type":43},"2024-08-05",{"date":80,"type":21},"2029-03-31",{"name":82,"class":83},"Wake Forest University Health Sciences","OTHER",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":97,"conditions":98,"keywords":106,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":84},"100517290","comorbidities-resolution-after-mgb-surgery-and-change-in-body-composition-100517290","NCT06015620","Comorbidities Resolution After MGB Surgery and Change in Body Composition","CoMOrbidities Resolution After Mini-GAstric Bypass Surgery for Morbid Obesity and Change in BOdy Composition: A Prospective Cohort Study (MOGAMBO Study)","MOGAMBO","Inclusion Criteria:\n\n* All patients undergoing laparoscopic MGB surgery for morbid obesity and it's associated comorbidities\n\nExclusion Criteria:\n\n* Patients not giving consent for the study\n* All patients who were undergoing a redo-procedure for recurrence were excluded from the study","65 Years",{"count":95,"type":21},35,"OBSERVATIONAL","This observational study aims to learn about the correlation between the improving comorbidities associated with obesity after MGB (Mini-Gastric Bypass) surgery and changes in body composition in morbidly obese patients. The main questions it aims to answer are:\n\nTo study the correlation between the improving comorbidities associated with obesity after MGB(Mini-Gastric Bypass) surgery and changes in body composition.\n\nOther objectives are:\n\n* Changes in the parameters of the metabolic syndrome after surgery\n* Changes in the cardiovascular risk biomarkers after metabolic surgery\n* Emergence in complications arising out of surgery requiring any intervention or causing a prolonged hospital stay, or requiring additional outpatient visits.\n\nType of Study: An observational study in which participants with morbid obesity will undergo mini-gastric bypass surgery as per routine protocol. No separate experimental interventions will be done in the study for the participants.",[99,100,101,102,103,30,104,105],"Morbid Obesity","Type2diabetes","Sleep Apnea","Hypothyroidism","Hypertension","Non-Alcoholic Fatty Liver Disease","Chronic Venous Hypertension With Ulcer",[107,108,109,110,111,112,113,114,115],"morbid obesity","OSA","mini gastric bypass","metabolic surgery","polysomnography","metabolic syndrome","DEXA scan","bioelectrical impedance","body composition","2026-02-16",{"date":118,"type":43},"2026-02-18",{"date":120,"type":43},"2023-09-01",{"date":122,"type":21},"2027-03-30",{"name":124,"class":83},"All India Institute of Medical Sciences, Bhubaneswar",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":135,"conditions":136,"keywords":140,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":84},"100562511","efficacy-of-probucol-combined-with-statins-treatment-for-ischemic-stroke-100562511","NCT06604117","Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke","A Prospective, Open-label Study Evaluating the Effects of Probucol Combined with Statins on Atherosclerotic Characteristics and Prognosis in Patients with Ischemic Stroke","EPCIS","Inclusion Criteria:\n\n1. Aged 18 years or older.\n2. Diagnosed with ischemic stroke (IS) confirmed by cranial CT\u002FMRI.\n3. Onset of stroke within the last 30 days.\n4. Evidence of atherosclerosis (AS) in at least one artery (carotid, coronary, aorta, renal, or peripheral arteries) identified through neck CTA, coronary CTA, or ultrasound examination of lower extremity arteries.\n5. Signed informed consent.\n\nExclusion Criteria:\n\n1. History of allergy to Probucol or statins.\n2. Non-atherosclerotic arterial stenosis, such as vasculitis, moyamoya disease, or arterial dissection.\n3. Potential cardiac embolic sources, such as atrial fibrillation, artificial heart valves, endocarditis, or patent foramen ovale.\n4. Known bleeding tendencies or hemorrhagic diseases, such as thrombocytopenia (platelet count \\< 100 × 10\\^9\u002FL), hemorrhagic stroke, or gastrointestinal bleeding.\n5. Severe myocardial diseases such as myocardial infarction (MI) or myocarditis.\n6. Liver (ALT or AST \\> twice the upper limit of normal) or kidney (creatinine \\> 1.5 times the upper limit of normal or glomerular filtration rate \\< 50 ml\u002Fmin) dysfunction.\n7. Ventricular tachycardia, bradycardia, torsades de pointes, or syncopal episodes of cardiac origin.\n8. Prolonged QT interval or conditions that may prolong the QT interval, such as certain medications.\n9. Suffering from a severe illness with a life expectancy of less than one year or unable to cooperate due to cognitive or psychological issues.\n10. Use of Probucol or any lipid-lowering medication other than statins, ezetimibe, and PCSK9 inhibitors within the 30 days prior to enrollment, including bile acid sequestrants, fibrates, and other similar drugs.\n11. Pregnant or breastfeeding individuals, those trying to conceive.\n12. Concurrent participation in another clinical trial involving investigational drugs or devices within the past 30 days.\n13. Planned surgery or intervention that would require discontinuation of the study medication during the study period.\n14. Any reason, known to the participant and investigator, that would prevent the participant from adhering to the study protocol or follow-up.\n15. Other conditions determined by the investigator that may require exclusion.",{"count":134,"type":21},200,"The goal of this clinical trial is to evaluate whether the combination of Probucol with statin therapy can reduce the risk of vascular events and improve atherosclerosis outcomes in adults with ischemic stroke and confirmed atherosclerosis. The main questions it aims to answer are:\n\nDoes adding Probucol to statin therapy reduce plaque burden more effectively than statins alone? Does the combination therapy lead to fewer cardiovascular and cerebrovascular events compared to statins alone? Researchers will compare participants receiving standard statin therapy to those receiving statins combined with Probucol to assess differences in plaque burden and the occurrence of vascular events.\n\nParticipants will:\n\nChoose either standard statin therapy (with possible addition of ezetimibe or PCSK9 inhibitors) or the same therapy combined with Probucol 0.5g twice daily.\n\nAttend regular follow-up visits for monitoring atherosclerosis features and cardiovascular health over a 3-year period.\n\nUndergo imaging studies to evaluate changes in atherosclerosis and blood tests to monitor lipid levels and other biomarkers.",[137,138,30,139],"Ischemic Stroke","Atherosclerosis of Artery","Statin",[141,139,69,142,143,144],"Probucol","Ischemic stroke","Plaque burden","Lipid-lowering treatment","2025-03-20",{"date":147,"type":43},"2025-03-25",{"date":149,"type":43},"2024-10-17",{"date":151,"type":21},"2027-10",{"name":153,"class":83},"Xuanwu Hospital, Beijing",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":161,"targetDuration":163,"studyType":96,"phases":4,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":84},"100209903","familial-hypercholesterolemia-canada--hypercholesterolemie-familiale-canada-100209903","NCT02009345","Familial Hypercholesterolemia Canada \u002F Hypercholesterolemie Familiale Canada","FHCanada","Inclusion Criteria:\n\n* Clinical diagnostic criteria for FH, which are:\n\n  * Family and\u002For personal history of high cholesterol\n  * Family and\u002For personal history of heart disease\n  * Abnormal growth on tendons, accumulation of fatty material in the eye\n* Family history of FH\n* Severe disorder of cholesterol and other lipids in the blood\n\nExclusion Criteria:\n\nNo exclusion criterion",{"count":162,"type":21},6000,"15 Years","Familial hypercholesterolemia (FH) is the most frequent genetic lipoprotein disorder associated with premature CAD. In Canada, the burden of disease is estimated to be approximately 83,500 patients. The goal of this initiative is to create a registry of subjects with FH across Canada. Rare diseases of lipoprotein metabolism are also included. Using a \"hub and spoke\" model, the registry extends in various communities to link primary care physicians with provincial academic centers. The registry includes clinical, biochemical and demographic information. Specimens (plasma\u002Fserum and DNA) are collected for biobanking. The \"local\" portion of the registry is available for clinicians to manage patient care, and identify relatives for screening and treatment (cascade screening). The Canada-wide registry, which is completely anonymized, will be made available to provide advice to general practitioners and to support collaborative studies in biomedical, clinical, health outcomes and health economics research. The data extracted for the provincial portion of the database will allow administrative database research that will provide important information to key stakeholders and permit allocation of resources. It will also allow a sound and uniform rationale for the use of novel therapeutic agents and provide expert advice to regulatory agencies. At the Canadian level, the database will allow clinicians and researchers to determine the burden of disease and the long-term effects of treatment. Through the creation of a Canada-wide network of academic clinics, integrating lipid specialists, endocrinologists and cardiologists, the Canadian FH registry will lead to significant benefits for FH patients, clinicians and researchers, biopharmaceutical industry and government.",[166,30],"Familial Hypercholesterolemia",[168,169,170,171],"Familial hypercholesterolemia,","High LDL-cholesterol","Registry","Coronary artery disease","2023-10-02",{"date":174,"type":43},"2023-10-04",{"date":176,"type":4},"2013-11",{"date":178,"type":21},"2028-11",{"name":180,"class":83},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":189,"sex":16,"minAge":17,"maxAge":93,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":192,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":84},"100513186","short-term-fat-overfeeding-on-the-effects-of-liver-metabolism-100513186","NCT05962190","Short-term Fat Overfeeding on the Effects of Liver Metabolism","The Effect of Short-term Overconsumption of Specific Dietary Nutrients on Liver and Adipose Tissue Metabolism.","FOS","Inclusion Criteria:\n\n* The participant is willing and able to give informed consent for participation in the study.\n* Male or Female, aged ≥18 or ≤65 years.\n* Body Mass Index ≥19 ≤35 kg\u002Fm2\n* No medical condition or relevant drug therapy that is known to affect liver or adipose tissue metabolism.\n* Weight stable for the previous 3 months\n\nExclusion Criteria:\n\n* The participant is unwilling or unable to give informed consent for participation in the study. - Aged ≤18 or ≥65 years\n* Body Mass Index ≤19 or ≥35kg\u002Fm2\n* Blood haemoglobin \\\u003C135mg\u002FdL for men and \\\u003C120mg\u002FdL for women\n* Donated (or lost) ≥250 ml of blood in the previous two months.\n* On a weight loss diet or have decreased their body weight by \\>5% in the previous 3 months.\n* Have increased their body weight by \\>5% in the previous 3 months.\n* Any metabolic condition or relevant drug therapy\n* Current smoker\n* History of alcoholism or a greater than recommended alcohol intake (\\>30 g of alcohol daily for men and \\>20 g of alcohol daily for women)\n* Haemorrhagic disorders\n* Anticoagulant treatment\n* History of albumin allergy\n* Pregnant or nursing mothers\n* Women prescribed any contraceptive agent or device including oral contraceptives, hormone replacement therapy (HRT) or who have used these within the last 12 months History of severe claustrophobia\n* Presence of metallic implants, pacemakers, or are unwilling to remove any piercings\n* History of an eating disorder or any other psychological condition that may affect the participant's ability to adhere to study intervention\u002Fexperimental diets.",true,{"count":191,"type":21},26,[193],"NA","Despite work showing the overconsumption of saturated fatty acids (SFA) to be metabolically deleterious, debate continues about whether there is a link between SFA and cardiovascular disease risk. To explore this, we are undertaking a human in vivo parallel-design study, comparing two isocaloric high-fat diets; one enriched with SFA and the other enriched with unsaturated fatty acids (UFAs), to determine the impact of dietary fat composition on postprandial metabolism, liver fat, cardiac fat and cardiac function.",[196,197,30,198],"Liver Fat","Cardiac Function","Adiposity","2023-07-18",{"date":201,"type":43},"2023-07-27",{"date":203,"type":43},"2023-02-15",{"date":205,"type":21},"2028-02",{"name":207,"class":83},"University of Oxford"]